These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

184 related items for PubMed ID: 37248064

  • 1. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
    Liu YF, Hou N, Shi YJ, Li CX, Gao YJ, Liu LN.
    Zhonghua Yi Xue Za Zhi; 2023 Jun 06; 103(21):1638-1642. PubMed ID: 37248064
    [Abstract] [Full Text] [Related]

  • 2. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
    Meltzer ME, Lisman T, de Groot PG, Meijers JC, le Cessie S, Doggen CJ, Rosendaal FR.
    Blood; 2010 Jul 08; 116(1):113-21. PubMed ID: 20385790
    [Abstract] [Full Text] [Related]

  • 3. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
    Soliman M, Osman N, Hefnawy S, El Hawy MA.
    Pediatr Hematol Oncol; 2022 May 08; 39(4):318-328. PubMed ID: 34668834
    [Abstract] [Full Text] [Related]

  • 4. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
    Erem C, Kocak M, Nuhoglu I, Yilmaz M, Ucuncu O.
    Eur J Endocrinol; 2009 May 08; 160(5):863-8. PubMed ID: 19233920
    [Abstract] [Full Text] [Related]

  • 5. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism.
    Ermantas N, Guldiken S, Demir M, Tugrul A.
    Clin Appl Thromb Hemost; 2010 Oct 08; 16(5):568-73. PubMed ID: 19959491
    [Abstract] [Full Text] [Related]

  • 6. Active PAI-1 as marker for venous thromboembolism: case-control study using a comprehensive panel of PAI-1 and TAFI assays.
    Bollen L, Peetermans M, Peeters M, Van Steen K, Hoylaerts MF, Declerck PJ, Verhamme P, Gils A.
    Thromb Res; 2014 Nov 08; 134(5):1097-102. PubMed ID: 25193405
    [Abstract] [Full Text] [Related]

  • 7. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
    Jönsson Rylander AC, Lindgren A, Deinum J, Bergström GM, Böttcher G, Kalies I, Wåhlander K.
    J Thromb Haemost; 2017 Apr 08; 15(4):758-769. PubMed ID: 28135035
    [Abstract] [Full Text] [Related]

  • 8. Influence of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 gene polymorphisms on tissue-type plasminogen activator-induced recanalization in ischemic stroke patients.
    Fernandez-Cadenas I, Alvarez-Sabin J, Ribo M, Rubiera M, Mendioroz M, Molina CA, Rosell A, Montaner J.
    J Thromb Haemost; 2007 Sep 08; 5(9):1862-8. PubMed ID: 17723126
    [Abstract] [Full Text] [Related]

  • 9. Thrombin activatable fibrinolysis inhibitor antigen levels are inversely correlated with plasminogen activator inhibitor-1 antigen levels in hyperthyroid patients.
    Akinci B, Comlekci A, Yener S, Demir T, Ozcan MA, Bayraktar F, Yesil S.
    Endocr J; 2007 Aug 08; 54(4):593-9. PubMed ID: 17690487
    [Abstract] [Full Text] [Related]

  • 10. The relationship among TAFI, t-PA, PAI-1 and F1 + 2 in type 2 diabetic patients with normoalbuminuria and microalbuminuria.
    Chudý P, Kotuličová D, Staško J, Kubisz P.
    Blood Coagul Fibrinolysis; 2011 Sep 08; 22(6):493-8. PubMed ID: 21519232
    [Abstract] [Full Text] [Related]

  • 11. Blood coagulation and fibrinolysis in patients with Cushing's syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels.
    Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H.
    J Endocrinol Invest; 2009 Feb 08; 32(2):169-74. PubMed ID: 19411818
    [Abstract] [Full Text] [Related]

  • 12. Plasminogen activator inhibitor-1 and thrombin activatable fibrinolysis inhibitor levels in non-alcoholic steatohepatitis.
    Yener S, Akarsu M, Demir T, Akinci B, Sagol O, Bayraktar F, Ozcan MA, Tankurt E, Yesil S.
    J Endocrinol Invest; 2007 Nov 08; 30(10):810-9. PubMed ID: 18075282
    [Abstract] [Full Text] [Related]

  • 13. Fibrinolytic Changes in Women with Preeclampsia.
    Godtfredsen AC, Sidelmann JJ, Dolleris BB, Jørgensen JS, Johansen EKJ, Pedersen MFB, Palarasah Y, Gram JB.
    Clin Appl Thromb Hemost; 2022 Nov 08; 28():10760296221126172. PubMed ID: 36217728
    [Abstract] [Full Text] [Related]

  • 14. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
    Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, Morser J, Verhallen P.
    Thromb Res; 2000 May 15; 98(4):333-42. PubMed ID: 10822080
    [Abstract] [Full Text] [Related]

  • 15. Baseline fibrinolytic state and the risk of future venous thrombosis. A prospective study of endogenous tissue-type plasminogen activator and plasminogen activator inhibitor.
    Ridker PM, Vaughan DE, Stampfer MJ, Manson JE, Shen C, Newcomer LM, Goldhaber SZ, Hennekens CH.
    Circulation; 1992 May 15; 85(5):1822-7. PubMed ID: 1572039
    [Abstract] [Full Text] [Related]

  • 16. Assessment of fibrinolytic markers in patients with deep vein thrombosis.
    Sharma S, Uppal V, Senee HK, Ahluwalia J, Das R, Varma N, Malhotra P, Kumar N.
    Blood Coagul Fibrinolysis; 2022 Mar 01; 33(2):113-118. PubMed ID: 35140191
    [Abstract] [Full Text] [Related]

  • 17. The hyperfibrinolytic state of mice with combined thrombin-activatable fibrinolysis inhibitor (TAFI) and plasminogen activator inhibitor-1 gene deficiency is critically dependent on TAFI deficiency.
    Vercauteren E, Peeters M, Hoylaerts MF, Lijnen HR, Meijers JC, Declerck PJ, Gils A.
    J Thromb Haemost; 2012 Dec 01; 10(12):2555-62. PubMed ID: 23083123
    [Abstract] [Full Text] [Related]

  • 18. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis.
    van Tilburg NH, Rosendaal FR, Bertina RM.
    Blood; 2000 May 01; 95(9):2855-9. PubMed ID: 10779431
    [Abstract] [Full Text] [Related]

  • 19. Bispecific targeting of thrombin activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 by a heterodimer diabody.
    Develter J, Booth NA, Declerck PJ, Gils A.
    J Thromb Haemost; 2008 Nov 01; 6(11):1884-91. PubMed ID: 18752580
    [Abstract] [Full Text] [Related]

  • 20. Blood coagulation and fibrinolysis in patients with acromegaly: increased plasminogen activator inhibitor-1 (PAI-1), decreased tissue factor pathway inhibitor (TFPI), and an inverse correlation between growth hormone and TFPI.
    Erem C, Nuhoglu I, Kocak M, Yilmaz M, Sipahi ST, Ucuncu O, Ersoz HO.
    Endocrine; 2008 Jun 01; 33(3):270-6. PubMed ID: 19016004
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.